Standard & Poor's
http://www2.standardandpoors.comStandard & Poor’s, a division of McGraw-Hill (NYSE: MHP), produces financial research and analysis on stocks and bonds. It provides credit ratings on public and private corporations and is designated as a Nationally Recognized Statistical Rating Organization (NRSRO) by the SEC. The firm’s long-term credit ratings range from “AAA” to “D” and its short-term credit ratings range from “A-1” to “D”. Standard & Poor’s also publishes indexes including the S&P 500.
View Older Stories
-
'Vintage Values 2021': Morgan Stanley Presents 15 Stocks to Hold for 12 Months
-
Costco (COST), Micron (MU), Twilio (TWLO), United Airlines (UAL) Among Stocks Added to Dave Portnoy-Backed BUZZ ETF
-
UPDATE: Raymond James Downgrades Gilead Sciences (GILD) to Market Perform
-
UBS Downgrades Gilead Sciences (GILD) to Neutral; Balanced Risk/Reward Into Remdesivir Readout
-
S&P 500 slips after report on coronavirus drug trial
-
BMO Capital Downgrades Gilead Sciences (GILD) to Market Perform; Risk/Reward Unfavorable
-
Pre-Open Movers 02/03: (INSM) (AIMT) (GILD) Higher; (NKTR) (CHKP) (NOC) Lower (more...)
-
S&P 500 gains, Nasdaq hits new high as investors eye earnings, coronavirus
-
S&P ends near flat as Citigroup results sink banks; Nasdaq hits new high
-
Pre-Open Stock Movers 12/20: (AGEN) (TLRY) (PTE) Higher; (DBVT) (ADMA) (SPPI) Lower (more...)
-
Maverick's 13F Shows New Stakes in Microsoft (MSFT), T-Mobile (TMUS), Increase in Envision (EVHC) (More)
-
Maverick Capital's 13F Shows New Stakes in Dow (DOW), MGM (MGM), Molson (TAP) (more...)
-
Pharma, Biotech Stocks Surge as Trump's Draft Order on Drug Prices Seen as Favorable (IBB) (XBI)
-
Maverick's 13F Shows New Stakes in Envision (EVHC), Walgreens (WBA), Increase in Inbev (BUD), Tesoro (TSO) (More...)
-
Maverick Capital Enters Martin Marietta (MLM), Raises Adobe (ADBE), Raises Aetna (AET) (more...) - 13F
-
Pre-Open Stock Movers 02/08: (MYGN) (COHR) (MCHP) Higher; (GALE) (USNA) (EYES) Lower (more...)
-
S&P 500 ekes out gain while banks drag on Dow
-
Maverick Capital 13F Shows New Stakes in Blue Buffalo Pet (BUFF), Dollar General (DG), Increase in ABI (BUD), Philip Morris (PM), (More...)
-
Biotech, Pharma Stocks Surge as IPAB Not Triggered
-
UPDATE: S&P Upgrades Gilead Sciences (GILD) to 'A'; Outlook Stable
-
U.S. biotech bloodbath hits hedge funds but some bargains emerge
-
S&P 500 bounces back after nearing August low
-
Wall Street climbs, S&P 500 posts best week since July
-
Many Stocks See Dramatic Reversals from Morning Lows
-
Tiger Management Shows New Stakes in Lumber Liquidators (LL), Sony (SNE), (more...)
-
Wall St higher ahead of Fed meeting
-
Wall Street bounces back after five-day selloff
-
Cooperman's Omega Advisors Shows News Stakes in GM (GM), Dow (DOW), Mobileye (MBLY); Sells Apple (AAPL)
-
Market Wrap: Markets Sink Amid Mixed Data; Q1 Earnings Season Reaches Peak; Initial Claims Hit 15-Year Lows
-
Market Wrap: Existing Sales Light in Feb.; Gilead Issues HCV Drug Warning; Investor May Push for McDonald's REIT
-
Market Wrap: U.S. Auto Sales Surge in Jan.; Oil Prices Continue Adding Gains; Office Goods Retailer M&A Nears
-
Market Wrap: Crude Prices Fuel Dec. Car Sales; Euro Slips to Near-Decade Lows; Fraud Hits Morgan Stanley
-
Market Wrap: Activist Zeroes in on Manitowoc; Shake Shack to go Public; Associated Estates Eyes Sale
-
GM (GM), Macy's (M) Among Barron's Top Picks for 2015 (GILD) (BAC)
-
Wall Street Looks to Soothe Biotech's Holiday Meltdown (GILD) (CELG) (AMGN)
-
Celgene (CELG), Related Stocks Decline Amid Biopharma Weakness
-
Market Wrap: Exting Sales Lag in Nov.; Achillion Ramps on ACH-3102, -3422 Results; Gilead Hit on Hep C Snub
-
Gilead Sciences (GILD) Should Attract Value and Growth Investors - Barron's
-
Market Wrap: Durable Orders Slip in Sept.; Facebook Fades on Results; FTC Targets AT&T
-
BofA/Merrill Lynch Sees New Era in Biotech Investing; Reinstates Coverage on 7 Large-Cap Names
-
Market Wrap: Mobile Bolsters Facebook in Q2; FAA Halts Israel Flights for Second Day; Earnings Aplenty
-
Market Wrap: Q1 Productivity Misses Views; New Coffee Deal for Mondelez; King's Post-IPO EPS Report
-
Stocks Choppy With Escalation of Ukraine Violence
-
Gilead Sciences (GILD) Price Target Slashed to $68 at Goldman Sachs
-
Stocks Sink; Margin Fears Take Center Stage
-
Blood-Bath in Nasdaq Stocks
-
Market Wrap: Rubicon Rips on Debut; Amazon Gets TV 'Fired' Up; Light Employment Gains in March
-
Deutsche Bank Defends Biotech; Says 2015 PEG Only 0.6x (GILD) (CELG) (ALXN) (IBB) (BIIB)
-
Stocks Weaker, Led by High-Beta Names
-
Biogen (BIIB), Celgene (CELG), and Gilead (GILD) Price Targets Raised at Deutsche Bank